TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15979810

Group type: EXPERIMENTAL
Intervention: Low-dose alcohol infusion (0.2 g/kg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 26
Study: 12103284

Group type: EXPERIMENTAL
Intervention: Continuous suturing method
Number of subjects: 1542

Group type: COMPARATOR
Intervention: Interrupted suturing method
Number of subjects: 1542

Group type: EXPERIMENTAL
Intervention: More rapidly absorbed polyglactin 910 suture material
Number of subjects: 1542

Group type: COMPARATOR
Intervention: Standard polyglactin 910 suture material
Number of subjects: 1542
Study: 10404829

Group type: EXPERIMENTAL
Intervention: GLP-2 infusion at a rate of 0.8 pmol/kg x min
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 8
Study: 7563322

Group type: EXPERIMENTAL
Intervention: Gasless laparoscopy‐assisted nephrectomy
Number of subjects: 7

Group type: COMPARATOR
Intervention: Open nephrectomy
Number of subjects: 7
Study: 1431013

Group type: EXPERIMENTAL
Intervention: Paroxetine (20-40 mg single doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paroxetine (therapeutic doses)
Number of subjects: 0
Study: 3882004

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30261799

Group type: EXPERIMENTAL
Intervention: Egalitarian/fair female authority
Number of subjects: 342

Group type: COMPARATOR
Intervention: Absolute male authority
Number of subjects: 342

Group type: COMPARATOR
Intervention: Higher male authority
Number of subjects: 342
Study: 31374985

Group type: EXPERIMENTAL
Intervention: SUCROSE (50 g sucrose)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: MALT (120 mg sucralose matched with 50 g maltodextrin)
Number of subjects: 11

Group type: COMPARATOR
Intervention: NNS (120 mg sucralose)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: SUCROSE
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: MALT
Number of subjects: 11

Group type: COMPARATOR
Intervention: NNS
Number of subjects: 11
Study: 29339723

Group type: EXPERIMENTAL
Intervention: fasoracetam (NFC-1) 400 mg BID for 4 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study: 27121662

Group type: EXPERIMENTAL
Intervention: Daily Enhancement of Meaningful Activity (DEMA) intervention
Number of subjects: 36

Group type: COMPARATOR
Intervention: Information Support (IS) control group
Number of subjects: 36
Study: 21802266

Group type: COMPARATOR
Intervention: High-mucilage dose (HM)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Low-mucilage dose (LM)
Number of subjects: 18
Study: 21765273

Group type: EXPERIMENTAL
Intervention: modified constraint‐induced movement therapy (mCIMT)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: bimanual intensive rehabilitation treatment (IRP)
Number of subjects: 105

Group type: COMPARATOR
Intervention: standard treatment (ST)
Number of subjects: 105
Study: 19820600

Group type: EXPERIMENTAL
Intervention: ORIF plus alpha-BSM (n = 24)
Number of subjects: 47

Group type: COMPARATOR
Intervention: ORIF alone (n = 28)
Number of subjects: 47
Study: 16627509

Group type: EXPERIMENTAL
Intervention: Group sessions of standardised intervention programmes for atopic dermatitis once weekly for six weeks
Number of subjects: 446
Study: 15113718

Group type: EXPERIMENTAL
Intervention: Breakfast cereal fortified with 440 microg folic acid, 1.8 mg vitamin B-6, and 4.8 microg vitamin B-12 for 12 weeks
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo cereal
Number of subjects: 189
Study: 11356801

Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control stretching exercises
Number of subjects: 16
Study: 9380321

Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg/day
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study: 1331830

Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms/kg i.v. given once prior to chemotherapy
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Granisetron 160 micrograms/kg i.v. given once prior to chemotherapy
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Granisetron (both doses)
Number of subjects: 125
Study: 4028771

Group type: EXPERIMENTAL
Intervention: Daily dressing changes every 24 hours
Number of subjects: 268

Group type: COMPARATOR
Intervention: Dressing changes every 72 hours
Number of subjects: 268
Study: 30929642

Group type: EXPERIMENTAL
Intervention: Peer support intervention
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 101
Study: 29917070

Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg
Number of subjects: 666

Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg
Number of subjects: 666

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 666

Group type: EXPERIMENTAL
Intervention: Golimumab (both doses)
Number of subjects: 666
Study: 26028408

Group type: EXPERIMENTAL
Intervention: Posture corrective exercise programme in addition to Physical Education classes; duration: 32 weeks
Number of subjects: 130

Group type: COMPARATOR
Intervention: Physical Education classes only; n = 46
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Posture corrective exercise programme; n = 42
Number of subjects: 130
Study: 24810870

Group type: EXPERIMENTAL
Intervention: escitalopram treatment
Number of subjects: 36

Group type: COMPARATOR
Intervention: placebo treatment
Number of subjects: 36
Study: 22549241

Group type: EXPERIMENTAL
Intervention: 10% Symphytum herb extract cream (Traumaplant®)
Number of subjects: 108
Study: 20430934

Group type: EXPERIMENTAL
Intervention: Exercise training (ET) for 12 weeks
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sedentary lifestyle (control)
Number of subjects: 37
Study: 18557690

Group type: EXPERIMENTAL
Intervention: Trauma-focused group therapy
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Present-centered group therapy
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Cognitive processing theory
Number of subjects: 420

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: CSP 420 (Trauma-focused vs Present-centered)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: CSP 420 (Clinically significant change categorization)
Number of subjects: 420
Study: 15872036

Group type: EXPERIMENTAL
Intervention: Pexelizumab 24 h infusion
Number of subjects: 337

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 337
Study: 11967034

Group type: EXPERIMENTAL
Intervention: Sodium ferric gluconate complex (SFGC)
Number of subjects: 2534

Group type: COMPARATOR
Intervention: Iron dextran
Number of subjects: 2534

Group type: COMPARATOR
Intervention: Placebo (bacteriostatic saline)
Number of subjects: 2534
Study: 10697623

Group type: COMPARATOR
Intervention: Carboplatin (C) alone
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Carboplatin (C) and Paclitaxel (P)
Number of subjects: 14
Study: 7729281

Group type: EXPERIMENTAL
Intervention: Mesalamine 4 g/day
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Mesalamine 1 g/day
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Mesalamine 2 g/day
Number of subjects: 310

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study: 2209837

Group type: EXPERIMENTAL
Intervention: Proglumide (a gastrin receptor antagonist)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 41
Study: 6452833

Group type: EXPERIMENTAL
Intervention: Aerosolized fenoterol
Number of subjects: 18

Group type: COMPARATOR
Intervention: Nebulized disodium cromoglycate (DSCG)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Ipratropium bromide (IPTB)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Combination of DSCG and IPTB
Number of subjects: 18

Group type: COMPARATOR
Intervention: Pulverized tablets of salbutamol, theophylline, and their combination
Number of subjects: 18
Study: 31415780

Group type: EXPERIMENTAL
Intervention: Nonsurgical treatment for stress urinary incontinence
Number of subjects: 106
Study: 28262140

Group type: EXPERIMENTAL
Intervention: Neurofeedback with medication (NF condition)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Medication only condition (Control)
Number of subjects: 36
Study: 26468123

Group type: EXPERIMENTAL
Intervention: Selenate (200 or 400 μg/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selenomethionine (200 μg/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selenate (400 μg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23926583

Group type: EXPERIMENTAL
Intervention: Light-activated disinfection (LAD) with FotoSan
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (mechanical cleaning alone)
Number of subjects: 80
Study: 21877766

Group type: EXPERIMENTAL
Intervention: JP formulation of pitavastatin 2 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: EU formulation of pitavastatin 2 mg
Number of subjects: 60
Study: 19037684

Group type: EXPERIMENTAL
Intervention: Persian WORC
Number of subjects: 150
Study: 17479142

Group type: EXPERIMENTAL
Intervention: Treatment in stroke units
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined stroke units (offering both acute medical treatment and rehabilitation)
Number of subjects: 0
Study: 15176282

Group type: EXPERIMENTAL
Intervention: Disposable pull-ups
Number of subjects: 0

Group type: COMPARATOR
Intervention: Disposable nappies
Number of subjects: 0
Study: 11809093

Group type: EXPERIMENTAL
Intervention: Oxygen enrichment to 24% at 3800 m
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ambient air conditions
Number of subjects: 12
Study: 9710685

Group type: EXPERIMENTAL
Intervention: pravastatin (20-40 mg)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: vitamin E
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: pravastatin + vitamin E
Number of subjects: 220

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 220
Study: 7991936

Group type: EXPERIMENTAL
Intervention: Insulin plus glipizide (3 x 10 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Insulin alone
Number of subjects: 10
Study: 2499150

Group type: EXPERIMENTAL
Intervention: Ketoconazole (200 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Terbinafine (500 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31188707

Group type: EXPERIMENTAL
Intervention: Otago Exercise Programme (OEP) with behavior change support
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Otago Exercise Programme (OEP) without behavior change support
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 124
Study: 29354987

Group type: EXPERIMENTAL
Intervention: Acupuncture regulating qi based on the compatibility of the five meridians, 30 min sessions, three times a week for 8 weeks.
Number of subjects: 57

Group type: COMPARATOR
Intervention: Rabeprazole orally, for 8 weeks.
Number of subjects: 57
Study: 25326831

Group type: EXPERIMENTAL
Intervention: Lippia citriodora extract-PLX(®)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Almond beverage
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Combination of both supplements (PLX(®) and almond beverage)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 23281041

Group type: EXPERIMENTAL
Intervention: Add teriparatide 20 µg/day
Number of subjects: 168

Group type: COMPARATOR
Intervention: Switch to teriparatide 20 µg/day
Number of subjects: 168
Study: 21079762

Group type: EXPERIMENTAL
Intervention: rPA formulated with Alhydrogel® (50 µg)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: rPA formulated with Alhydrogel® (25 µg)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Buffered saline placebo
Number of subjects: 73
Study: 18431541

Group type: COMPARATOR
Intervention: Standard physical therapy (hot pack, ultrasound therapy, exercise program)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Traction therapy in addition to standard physical therapy
Number of subjects: 42
Study: 16842389

Group type: EXPERIMENTAL
Intervention: 10 mg rac-albuterol
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 400 microg rac-albuterol
Number of subjects: 14
Study: 12805340

Group type: EXPERIMENTAL
Intervention: Carrier oil only
Number of subjects: 313

Group type: COMPARATOR
Intervention: Carrier oil with fractionated oils
Number of subjects: 313

Group type: COMPARATOR
Intervention: Pure essential oils of lavender, bergamot, and cedarwood
Number of subjects: 313
Study: 11228951

Group type: EXPERIMENTAL
Intervention: Aerobic treadmill exercise (AEX) for 3 months, 3 times/week
Number of subjects: 5
Study: 8899259

Group type: EXPERIMENTAL
Intervention: Depot-medroxyprogesterone acetate (DMPA)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Cyclofem
Number of subjects: 600
Study: 1666179

Group type: EXPERIMENTAL
Intervention: HOE 427 (ebiratide), administered intravenously in a pulsatile mode 4 times (120 micrograms each) at 2200, 2300, 2400 and 0100
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7066127

Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.1 or 0.2 mg i.v. on patient demand using the 'Cardiff' palliator
Number of subjects: 51
Study: 30759283

Group type: EXPERIMENTAL
Intervention: 60‐s 2% chlorhexidine digluconate (CHX) application
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 60‐s ozone application
Number of subjects: 105

Group type: COMPARATOR
Intervention: No disinfectant (control)
Number of subjects: 105
Study: 28366114

Group type: EXPERIMENTAL
Intervention: Facilitated psychiatric advance directive (FPAD) by peer support specialists
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Facilitated psychiatric advance directive (FPAD) by nonpeer clinicians
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Facilitated psychiatric advance directive (FPAD) with peer support specialists or nonpeer clinicians
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Facilitated psychiatric advance directive (FPAD)
Number of subjects: 145
Study: 25269512

Group type: EXPERIMENTAL
Intervention: Equine-assisted psychotherapy (EAP)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Canine-assisted psychotherapy (CAP)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Enhanced social skills psychotherapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Regular hospital care
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 1:1 clinical observation
Number of subjects: 90
Study: 23816513

Group type: EXPERIMENTAL
Intervention: ALB×1
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: MBZ×1
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: ALB×2
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: MBZ×2
Number of subjects: 385
Study: 21078941

Group type: EXPERIMENTAL
Intervention: Quinine treatment
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: In vitro quinine sensitivity testing
Number of subjects: 66
Study: 19278356

Group type: EXPERIMENTAL
Intervention: Altitude hypoxia (14% O2)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Room air (21% O2)
Number of subjects: 6
Study: 17431728

Group type: EXPERIMENTAL
Intervention: Spa therapy (n = 10) - 10-day course including thermal pool baths at 37 degrees C for 20 min two times daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Spa therapy (n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Drug therapy (n = 10) - NSAIDs and paracetamol
Number of subjects: 20
Study: 14963281

Group type: EXPERIMENTAL
Intervention: Aspirin 650 mg/d
Number of subjects: 83

Group type: COMPARATOR
Intervention: Ticlopidine 500 mg/d
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Aspirin dose reduction from 1300 to 325 or 81 mg/d
Number of subjects: 83
Study: 11164206

Group type: EXPERIMENTAL
Intervention: Acute metabolic alkalosis (NaHCO(3))
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Acute metabolic acidosis (NH(4)Cl)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (NaCl)
Number of subjects: 15
Study: 9393518

Group type: EXPERIMENTAL
Intervention: True-block group (30 mL 0.5% bupivacaine)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo-block group
Number of subjects: 34
Study: 7965420

Group type: EXPERIMENTAL
Intervention: Tartrazine (1, 2, 5, 10, 20, 50 mg) administered randomly each morning for 21 days
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo administered randomly each morning for 21 days
Number of subjects: 200
Study: 3298594

Group type: EXPERIMENTAL
Intervention: Home treatment
Number of subjects: 82

Group type: COMPARATOR
Intervention: Hospital treatment
Number of subjects: 82
Study: 30353607

Group type: EXPERIMENTAL
Intervention: Single-channel applicator
Number of subjects: 151

Group type: COMPARATOR
Intervention: Fletcher group
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Single-channel group
Number of subjects: 151
Study: 26383044

Group type: EXPERIMENTAL
Intervention: Approach-oriented coping under high disease controllability
Number of subjects: 92

Group type: COMPARATOR
Intervention: Avoidance-oriented coping under high disease controllability
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Approach-oriented coping under low disease controllability
Number of subjects: 92

Group type: COMPARATOR
Intervention: Avoidance-oriented coping under low disease controllability
Number of subjects: 92

Group type: COMPARATOR
Intervention: Experimental conditions (approach vs avoidance)
Number of subjects: 92
Study: 25007362

Group type: EXPERIMENTAL
Intervention: Econazole nitrate foam 1%
Number of subjects: 495

Group type: COMPARATOR
Intervention: Foam vehicle
Number of subjects: 495
Study: 22405255

Group type: EXPERIMENTAL
Intervention: Misoprostol (200 μg vaginally, 2 tablets, 3 hours before abortion)
Number of subjects: 4972

Group type: COMPARATOR
Intervention: Placebo (2 tablets, 3 hours before abortion)
Number of subjects: 4972

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 4972

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4972
Study: 20173276

Group type: EXPERIMENTAL
Intervention: Educational video (Syphilis and Men)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control group (no video)
Number of subjects: 206
Study: 17710126

Group type: EXPERIMENTAL
Intervention: Four‐Agents‐Decoction (Si Wu Tang)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 15552635

Group type: EXPERIMENTAL
Intervention: Morning dosing of 1000 mg extended-release divalproex sodium
Number of subjects: 100

Group type: COMPARATOR
Intervention: Evening dosing of 1000 mg extended-release divalproex sodium
Number of subjects: 100
Study: 11518478

Group type: EXPERIMENTAL
Intervention: Li 1370 (240 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 10097485

Group type: EXPERIMENTAL
Intervention: Classroom only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Classroom plus school-as-community
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 8159022

Group type: EXPERIMENTAL
Intervention: Normothermic cardiopulmonary bypass (37 degrees C)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Hypothermic cardiopulmonary bypass (27 degrees C)
Number of subjects: 52
Study: 3414595

Group type: EXPERIMENTAL
Intervention: Low-fat diets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased fatty acid chain length and saturation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased dietary cholesterol levels
Number of subjects: 0
Study: 29366988

Group type: EXPERIMENTAL
Intervention: RG7652 (PCSK9 inhibiting antibody)
Number of subjects: 0
Study: 26865332

Group type: EXPERIMENTAL
Intervention: 4-Fr catheter
Number of subjects: 254

Group type: COMPARATOR
Intervention: 5-Fr catheter
Number of subjects: 254
Study: 24438596

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gel (0.2%) application
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard treatment (control)
Number of subjects: 45
Study: 23381064

Group type: EXPERIMENTAL
Intervention: Physician plus nurse observation during withdrawal
Number of subjects: 502

Group type: COMPARATOR
Intervention: Routine colonoscopy
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Nurse observation
Number of subjects: 502
Study: 20490383

Group type: EXPERIMENTAL
Intervention: Full-mouth therapy of periodontitis (nonsurgical treatment) between 22 and 30 weeks of gestation
Number of subjects: 54

Group type: COMPARATOR
Intervention: No treatment (group 3)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Declined treatment (group 2)
Number of subjects: 54
Study: 18550744

Group type: EXPERIMENTAL
Intervention: GSPBRT‐PCR
Number of subjects: 600

Group type: COMPARATOR
Intervention: Blood culture
Number of subjects: 600
Study: 16898856

Group type: EXPERIMENTAL
Intervention: Ranitidine effervescent tablets (Zantac EFFERdose)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Ranitidine syrup (Zantac)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Adverse events reported
Number of subjects: 102
Study: 14980948

Group type: EXPERIMENTAL
Intervention: 0.5 microg/kg dexmedetomidine
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.5% lidocaine + 1 mL isotonic saline
Number of subjects: 30
Study: 11601114

Group type: EXPERIMENTAL
Intervention: Various types of osteosyntheses including sliding hip screw, neck screws, intramedullary nails with neck screw, retrograde intramedullary nails, external fixation, cannulated screws, various plates, tension band wiring, threaded K-pins, and arthroplasties.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bone grafting and substitutes (biologically inert, osteoconductive, or osteoinductive) and osteoinductive growth factors and hormones as supplements to treatment.
Number of subjects: 0
Study: 9834259

Group type: EXPERIMENTAL
Intervention: Additional omeprazole, 20 mg at bedtime
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ranitidine, 150 mg at bedtime
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ranitidine, 300 mg at bedtime
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo at bedtime
Number of subjects: 12

Group type: COMPARATOR
Intervention: Omeprazole at bedtime
Number of subjects: 12
Study: 7930273

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (1) streptokinase with intravenous heparin; (2) streptokinase with subcutaneous heparin; (3) accelerated-dose rt-PA with intravenous heparin; (4) combination of streptokinase and conventionally dosed rt-PA with intravenous heparin
Number of subjects: 559
Study: 3207350

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice per day
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg in a single dose at night
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8